| Literature DB >> 32318262 |
Ruixue Huang1, Xiaodan Liu2, He Li1, Yao Zhou1,2, Ping-Kun Zhou2,3.
Abstract
BACKGROUND: Radiation damage to normal tissues is a serious concern. P53 is a well-known transcription factor which is closely associated with radiation-induced cell damage. Increasing evidence has indicated that regulation of metabolism by p53 represents a reviving mechanism vital to protect cell survival. We aimed to explore the interactions of radiation-induced transcripts with the cellular metabolism regulated by p53.Entities:
Year: 2020 PMID: 32318262 PMCID: PMC7160934 DOI: 10.1186/s13578-020-00417-z
Source DB: PubMed Journal: Cell Biosci ISSN: 2045-3701 Impact factor: 7.133
Fig. 1Bioinformatic analysis of the mRNA expression alteration based on HBE cells with or without CRISPR/Cas9-mediated p53-knockout. a p53 knockout efficiency was determined using western blotting. b Quantitative measurement of differential expressed mRNA in HBE cells with (p53-/-) or without CRISPR/Cas9-mediated p53-knockout (p53-wt) after 4 Gy IR. c. A heatmap was illustrated to show the differential expressed mRNA in HBE cells with (p53-/-) or without CRISPR/Cas9-mediated p53-knockout (p53-wt) after 4 Gy IR. Pink represents upregulated mRNA, and purple represents down-regulated mRNA. d A volcano map was illustrated to show the differential expressed mRNA in HBE cells with (p53-/-) or without CRISPR/Cas9-mediated p53-knockout (p53-wt) after 4 Gy IR. Red represents upregulated mRNA, green represents down-regulated mRNA and grey represents the mRNA without expression change
Top 20 differential expressed genes/mRNAs in the p53-wt vs. p53-KO HBE cells post 4 Gy radiation
| Upregulated mRNA | Downregulated mRNA | ||||||
|---|---|---|---|---|---|---|---|
| Gene-ID | Fold change | log2 (fold) | Gene-ID | Fold change | log2 (fold) | ||
| DEFA6 | 78.33913 | 6.291661 | 1.38E−11 | C8orf86 | 0.130736 | − 2.93527 | 0.009803 |
| SLC3A1 | 20.16332 | 4.333661 | 0.003823 | LOC112268013 | 0.216001 | − 2.21089 | 0.00971 |
| SCN1A | 19.79819 | 4.307297 | 0.004904 | MATK | 0.217973 | − 2.19778 | 0.006171 |
| ENTHD1 | 16.45192 | 4.040184 | 0.013362 | TMEM56-RWDD3 | 0.252377 | − 1.98635 | 0.039409 |
| RSPH6A | 13.827 | 3.789416 | 0.001236 | SCT | 0.256374 | − 1.96368 | 0.023869 |
| CHRNA6 | 12.5158 | 3.645679 | 0.045863 | P2RY4 | 0.267326 | − 1.90333 | 0.014581 |
| SLC25A6 | 10.65712 | 3.413746 | 0.011851 | LCN2 | 0.303939 | − 1.71815 | 5.85E−15 |
| FAM163B | 9.699409 | 3.277897 | 7.21E−07 | SPRR2D | 0.306724 | − 1.70499 | 3.68E−13 |
| TAS1R3 | 9.304103 | 3.217867 | 0.000423 | SLC26A4 | 0.316586 | − 1.65933 | 4.28E−25 |
| RXFP4 | 8.349756 | 3.061734 | 0.005335 | POTEI | 0.318255 | − 1.65174 | 0.02425 |
| MANSC4 | 7.434827 | 2.894299 | 0.011991 | STK32A | 0.325094 | − 1.62107 | 1.93E−17 |
| GPR84 | 7.172444 | 2.842465 | 0.003795 | GPR39 | 0.326626 | − 1.61429 | 2.71E − 05 |
| U2AF1 | 6.906392 | 2.787932 | 0.00111 | CD69 | 0.336596 | − 1.57091 | 0.003493 |
| FAM19A3 | 6.628252 | 2.728628 | 0.026354 | LPAR6 | 0.338796 | − 1.56151 | 1.84E −07 |
| CES5A | 6.442318 | 2.68758 | 0.010618 | NT5E | 0.353169 | − 1.50157 | 2.36E−46 |
| KCNJ2 | 6.295374 | 2.654292 | 0.026678 | FLNC | 0.355741 | − 1.4911 | 1.45E−15 |
| SNCB | 6.047667 | 2.596379 | 0.044324 | INSC | 0.360171 | − 1.47325 | 0.021098 |
| MAP2K6 | 5.47041 | 2.451649 | 0.000226 | GZMB | 0.378744 | − 1.40071 | 4.97E−18 |
| LHFPL1 | 5.383789 | 2.428622 | 0.000288 | LOC102724219 | 0.389122 | − 1.3617 | 0.032583 |
| DEFA6 | 78.33913 | 6.291661 | 1.38E−11 | LGALS7B | 0.389833 | − 1.35907 | 0.002712 |
p < 0.05 represents significantly changed
Fig. 2GO analysis of significantly differential expressed mRNA based on HBE cells with or without CRISPR/Cas9-mediated p53-knockout. a Enrichment of mRNA significantly differential expressed in the biological process. b Enrichment of mRNA significantly differential expressed in the molecular function. c Enrichment of mRNA significantly differential expressed in the cellular component
Fig. 3Verification of selected mRNA. a KEGG analysis of significantly differential expressed mRNA in HBE cells with (p53-/-) or without CRISPR/Cas9-mediated p53-knockout (p53-wt) after 4 Gy IR. b five upregualted mRNA and five downregulated mRNA were selected to verify whether the expression trend consistence with microarray assay by qRT-PCR on HBE cells with CRISPR/Cas9-mediated p53-knockout
35 differential expressed metabolites in p53-wt vs.p53-KO HBE cells post 4 Gy radiation
| Metabolites | VIP* | log2 (FC) | Class | Sub class | |
|---|---|---|---|---|---|
| Erythronic acid lactone | 1.06922 | 0.6158 | 6.9E−05 | Lactones | Organoheterocyclic compounds |
| Hydroxylamine | 1.34941 | 0.19798 | 0.04045 | Homogeneous other non-metal compounds | Homogeneous non-metal compounds |
| 4-hydroxymandelic acid | 1.36889 | − 0.6996 | 0.00142 | Phenols | Benzenoids |
| Erythronic acid | 1.42277 | − 1.7093 | 0.00929 | Organooxygen compounds | Organic oxygen compounds |
| Epsilon-caprolactam | 1.34602 | − 0.7127 | 0.00061 | Lactams | Organoheterocyclic compounds |
| Allothreonine | 1.46924 | − 0.5049 | 0.00792 | Carboxylic acids and derivatives | Organic acids and derivatives |
| Metharbital | 1.41033 | − 1.0301 | 0.00381 | Diazines | Organoheterocyclic compounds |
| Nicotinic acid | 1.42734 | − 0.5283 | 0.00083 | Pyridines and derivatives | Organoheterocyclic compounds |
| 3,3-dimethyl-1-hydroxy-cyclohexene | 1.009 | − 1.3095 | 0.00151 | – | – |
| Cyanoalanine | 1.40793 | − 0.7455 | 9.4E−05 | – | – |
| 2,4-diaminobutyric acid | 1.4873 | − 0.793 | 0.03173 | Carboxylic acids and derivatives | Organic acids and derivatives |
| Isocitric acid | 1.43121 | − 1.3229 | 0.01103 | Carboxylic acids and derivatives | Organic acids and derivatives |
| Alpha-tocopherol | 1.47328 | − 1.0729 | 0.00435 | Prenol lipids | Lipids and lipid-like molecules |
| Arbutin | 1.06715 | − 1.2865 | 0.00725 | Organooxygen compounds | Organic oxygen compounds |
| 5-hydroxymethyl-2-furoic acid | 1.38372 | − 2.0063 | 0.00456 | Furans | Organoheterocyclic compounds |
| Alloxanoic acid | 1.15251 | − 2.265 | 0.0279 | – | – |
| 3-hydroxybenzoic acid | 1.4286 | − 1.47 | 0.00704 | Benzene and substituted derivatives | Benzenoids |
| 4-hydroxyphenylacetic acid | 1.34886 | − 0.7195 | 0.01778 | Phenol esters | Benzenoids |
| Succinylacetone | 1.00743 | − 3.6389 | 0.01924 | Keto acids and derivatives | Organic acids and derivatives |
| Chlorogenic acid | 1.01029 | − 2.1308 | 0.00706 | Organooxygen compounds | Organic oxygen compounds |
| Tocopherol acetate | 1.3993 | − 1.8671 | 0.01908 | Prenol lipids | Lipids and lipid-like molecules |
| Pseudo uridine | 1.24524 | − 0.4121 | 0.03491 | Nucleoside and nucleotide analogues | Nucleosides, nucleotides, and analogues |
| Epicatechin | 1.37918 | − 0.9262 | 0.01609 | Flavonoids | Phenylpropanoids and polyketides |
| O-phosphoethanolamine | 1.37653 | 0.87116 | 0.04621 | Organic phosphoric acids and derivatives | Organic acids and derivatives |
| Azelaic acid | 1.13179 | − 1.3106 | 0.00278 | Fatty Acyls | Lipids and lipid-like molecules |
| Beta-glutamic acid | 1.22441 | − 0.4523 | 0.03566 | – | – |
| Lactobionic acid | 1.34112 | − 1.0772 | 0.01633 | – | – |
| Arsenate | 1.03192 | − 1.9182 | 0.00398 | Miscellaneous mixed metal/non-metals | Mixed metal/non-metal compounds |
| Palatinitol | 1.27221 | − 0.7068 | 0.0263 | – | – |
| L-allothreonine | 1.38117 | − 0.6869 | 0.04396 | Purine nucleosides | Nucleosides, nucleotides, and analogues |
| Oleamide | 1.02286 | 0.2853 | 0.01158 | Fatty Acyls | Lipids and lipid-like molecules |
| 1,3-diphosphoglycerol | 1.12954 | 1.40969 | 0.02935 | – | – |
| D-erythro-sphingosine | 1.24636 | − 0.5613 | 0.02118 | Organonitrogen compounds | Organic nitrogen compounds |
| Phytosphingosine | 1.11889 | − 0.6993 | 0.0023 | Organonitrogen compounds | Organic nitrogen compounds |
A positive value indicates up regulation and a negative value indicates down regulation
* Vip variable important in projection, The larger the VIP, the greater the contribution of this variable to the grouping; log2 (FC): the ratio of the average expression amount of metabolites in the two groups of samples
Fig. 4Bioinformatic analysis of metabolomics. a A heatmap was used to visually represent upregulated and downregulated metabolites. b A volcano was used to visually represent upregulated and downregulated metabolites. c The interactions among altered metabolites were analyzed by pearson correlation analysis
Fig. 5Integrated transcriptomic and metabolomic analyses of p53-dependent metabolic pathways. a KEGG analysis of significantly altered metabolites. b The mRNA enrichment and metabolic pathway analyses was based on joint pathways using MetaboAnalyst 4.0. c The arachidonic acid metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout. d The nitrogen metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout
Integration of pathways of both the metabolites and metabolic genes
| Pathway name | Match status | P | Impact |
|---|---|---|---|
| Fructose and mannose metabolism | 1/40 | 0.37213 | 0.25641 |
| Tyrosine metabolism | 3/88 | 0.077606 | 0.22989 |
| Pyrimidine metabolism | 2/99 | 0.31535 | 0.22449 |
| Nitrogen metabolism | 2/10 | 0.0054 | 0.22222 |
| Glutathione metabolism | 3/56 | 0.024996 | 0.21818 |
| Glycolysis or Gluconeogenesis | 3/61 | 0.03124 | 0.2 |
| Phenylalanine metabolism | 1/21 | 0.21603 | 0.2 |
| Pyruvate metabolism | 1/45 | 0.40794 | 0.18182 |
| Arachidonic acid metabolism | 5/81 | 0.001919 | 0.175 |
| Propanoate metabolism | 1/48 | 0.42847 | 0.17021 |
| Purine metabolism | 2/166 | 0.57811 | 0.1697 |
| Thiamine metabolism | 1/14 | 0.14958 | 0.15385 |
| Biotin metabolism | 1/21 | 0.21603 | 0.15 |
| Taurine and hypotaurine metabolism | 1/16 | 0.1691 | 0.13333 |
| Retinol metabolism | 1/47 | 0.42171 | 0.13043 |
| Linoleic acid metabolism | 1/17 | 0.17869 | 0.125 |
| Drug metabolism-cytochrome P450 | 2/98 | 0.31104 | 0.1134 |
| Ether lipid metabolism | 1/39 | 0.36472 | 0.10526 |
| Nicotinate and nicotinamide metabolism | 2/42 | 0.082504 | 0.097561 |
| Alpha-Linolenic acid metabolism | 1/22 | 0.2251 | 0.095238 |
| Glycine, serine and threonine metabolism | 2/68 | 0.18248 | 0.089552 |
| Primary bile acid biosynthesis | 2/92 | 0.28513 | 0.087912 |
| Pentose phosphate pathway | 1/47 | 0.42171 | 0.086957 |
| Glycerophospholipid metabolism | 2/86 | 0.25918 | 0.070588 |
| Histidine metabolism | 1/32 | 0.31045 | 0.064516 |
| Fatty acid degradation | 2/102 | 0.32824 | 0.059406 |
| Starch and sucrose metabolism | 1/43 | 0.39386 | 0.047619 |
| Fatty acid biosynthesis | 1/129 | 0.78338 | 0.046875 |
| beta-Alanine metabolism | 1/44 | 0.40094 | 0.046512 |
| Cysteine and methionine metabolism | 1/71 | 0.56461 | 0.042857 |
| Glyoxylate and dicarboxylate metabolism | 1/56 | 0.47992 | 0.036364 |
| Sphingolipid metabolism | 1/58 | 0.49207 | 0.035088 |
| Folate biosynthesis | 1/61 | 0.50978 | 0.033333 |
| Metabolism of xenobiotics by cytochrome P450 | 2/145 | 0.50302 | 0.027778 |
| Steroid hormone biosynthesis | 1/199 | 0.90892 | 0.020202 |
Fig. 6Integrated transcriptomic and metabolomic analyses of p53-dependent metabolic pathways. a The glutathione metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout. b The glycolysis or gluconeogenes metabolism pathway with altered significantly mRNA (red) in HBE cells with CRISPR/Cas9-mediated p53-knockout. c GGT1, PLA2G, PTGS, GPX6, ALDOA, ACSS2, ALDH3A1, GGT6 expression levels were determined using qRT-PCR in HBE cells of p53-wt, p53-wt treated with 4 Gy radiation (p53-wt –IR), p53-/-, and p53-/- treated with 4 Gy radiation (p53-/- IR), respectively. The data are presented as the means ± SDs from three independent experiments; * p < 0.05 between different groups